Panacos to Report Fourth Quarter and Full Year 2005 Results
Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, announced today that the Company will report its fourth quarter and full year 2005 financial results after the U.S. Financial Markets close on Tuesday, February 14, 2006. Following the announcement, Panacos will hold a conference call to discuss the results and provide an update on the Company’s development programs. Dr. Samuel K. Ackerman, President and CEO, will lead the call.
Date: Tuesday, February 14, 2006 Time: 4:30 p.m. Eastern time Conference call access Internet: www.panacos.com Domestic dial-in: (800) 561-2601 International dial-in: (617) 614-3518
The conference call can be accessed via the web at www.panacos.com or by calling the conference dial-in between 4:15 and 4:25 p.m. and entering the passcode 27590120. A replay of the conference call will be available from 6:30 p.m. February 14, 2006 until Thursday, March 16, 2006, and can be accessed via the web at www.panacos.com or by dialing toll-free (888) 286-8010, and outside the U.S. (617) 801-6888 with passcode 17704662.
About Panacos
Panacos is developing the next generation of anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Panacos’ lead candidate, PA-457, is the first in a new class of oral HIV therapeutics under development called maturation inhibitors, discovered by Panacos scientists and their academic collaborators. By targeting a novel step in the virus life cycle, maturation inhibitors are designed to have potent activity against a broad range of HIV, including strains that are resistant to existing classes of drugs. Drug resistance is the most pressing problem in HIV therapy and the leading cause of treatment failure. Panacos’ proprietary discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion.
Except for the historical information contained herein, statements made herein are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks as set forth in the Company’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.